Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX)
(OTCQX: LXRP) today announced the publication of final study results
of the 2018 human clinical study evaluating CBD delivery and effectiveness
using its patented DehydraTECH(TM) powered TurboCBD(TM); capsules. According to
the update results were published in the peer reviewed medical journal, Advances
in Therapy, which focuses on clinical medicine and pharmaceutical research
and has been published continually since 1984. Lexaria reported several key
findings highlighted in the publication, including but not limited to: CBD
in-plasma levels with the 90mg dose of TurboCBD were significantly higher than
with the generic 90 mg dose at both 90 and 120 minutes; and only the 90 mg dose
of TurboCBD was elevated (i.e., greater than the placebo) at 30 minutes and
remained elevated at 4 hours.
To view the full press releases, visit http://ibn.fm/NseX1
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. is a global innovator in drug
delivery platforms. Its patented DehydraTECH(TM) drug delivery technology
changes the way Active Pharmaceutical Ingredients enter the bloodstream,
promoting healthier ingestion methods, lower overall dosing and higher
effectiveness for lipophilic active molecules. DehydraTECH increases
bio-absorption; reduces time of onset; and masks unwanted tastes for orally
administered bioactive molecules including cannabinoids, vitamins,
non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules.
Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry
for use in cannabinoid beverages, edibles and oral products; and to a
world-leading tobacco producer for the development of smokeless, oral-based
nicotine products. Lexaria operates a licensed in-house research laboratory and
holds a robust intellectual property portfolio with 16 patents granted and over
60 patents pending worldwide. For more information, visit the company’s website
at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
